Skip to main content

J&J Pharma R&D Signs On for Five More Years with Entelos

NEW YORK, March 16 (GenomeWeb News) - Johnson & Johnson Pharmaceutical Research & Development will collaborate with Entelos to research multiple therapeutic areas for five more years, Entelos said today.

 

Under the agreement, Entelos engineers and scientists will use the PhysioLab platforms to "support specific projects ... on behalf of J&JPRD and its affiliates," the company said in a statement.

 

Financial details were not provided.

 

As GenomeWeb News reported last week, Entelos is unalarmed about the recent downsizing at J&JPRD. The two companies also recently expanded a hemotology research collaboration.

 

"We believe J&JPRD's continued commitment to apply the power of biosimulation to the drug discovery and development decisions will lead to safer and more effective medicines for patients," Entelos president and CEO James Karis said in a statement.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.